AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards.
FDA delays verdict on AZ breast cancer drug
After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.
